OR WAIT null SECS
Sixty women between 40 and 60 years old were assigned to 28 days of supplementation with placebo, 250 mg of Cognizin, or 500 mg of Cognizin.
The University of Utah Brain Institute has brought forward results of a randomized, placebo-controlled trial on Cognizin brand citicoline and mental performance in 60 women. The trial was presented at the May 22 Annual Meeting of the Society of Biological Psychiatry in San Francisco.
Sixty women between 40 and 60 years old were assigned to 28 days of supplementation with placebo, 250 mg of Cognizin, or 500 mg of Cognizin. Participants were then assigned to cognitive tests and assessed with the Continuous Performance Test II, a test which measures attentional function.
Compared to placebo, both doses of Cognizin were linked to improved attention and ability to produce correct responses during the test. These results bode well for 250 mg of Cognizin as a low yet efficacious amount of citicoline for potential cognitive improvements.
“Citicoline has been shown to have a variety of cognitive-enhancing and neuroregenerative properties in pre-clinical and clinical studies,” says Deborah Yurgelun-Todd, PhD, director of the Cognitive Neuroimaging Laboratory at the University of Utah Brain Institute. “Our findings suggest that citicoline may mitigate the cognitive decline associated with normal aging and may ameliorate attentional deficits associated with psychiatric disorders.”